Trial · NCT00440193
Results by group66
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 66
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment | Rivaroxaban (Xarelto, BAY59-7939) | 2.1 | Percentage of participants | ||
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment | Enoxaparin/VKA | 3.0 | Percentage of participants | ||
| Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment | Rivaroxaban (Xarelto, BAY59-7939) | 4.0 | Percentage of participants | ||
| Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment | Enoxaparin/VKA | 5.1 | Percentage of participants | ||
| Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment | Rivaroxaban (Xarelto, BAY59-7939) | 2.9 | Percentage of participants | ||
| Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment | Enoxaparin/VKA | 4.2 | Percentage of participants | ||
| Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment | Rivaroxaban (Xarelto, BAY59-7939) | 0.9 | Percentage of participants | ||
| Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment | Enoxaparin/VKA | 1.6 | Percentage of participants | ||
| Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose) | Rivaroxaban (Xarelto, BAY59-7939) | 8.1 | Percentage of participants | ||
| Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose) | Enoxaparin/VKA | 8.1 | Percentage of participants | ||
| Percentage of Participants With All Deaths | Rivaroxaban (Xarelto, BAY59-7939) | All post-randomization | 2.4 | Percentage of participants | |
| Percentage of Participants With All Deaths | Enoxaparin/VKA | All post-randomization | 3.0 | Percentage of participants | |
| Percentage of Participants With All Deaths | Rivaroxaban (Xarelto, BAY59-7939) | Treatment-emergent (time window: 2 days) | 1.0 | Percentage of participants | |
| Percentage of Participants With All Deaths | Enoxaparin/VKA | Treatment-emergent (time window: 2 days) | 1.1 | Percentage of participants | |
| Percentage of Participants With All Deaths | Rivaroxaban (Xarelto, BAY59-7939) | Treatment-emergent (time window: 7 days) | 1.2 | Percentage of participants | |
| Percentage of Participants With All Deaths | Enoxaparin/VKA | Treatment-emergent (time window: 7 days) | 1.5 | Percentage of participants | |
| Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose) | Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | Percentage of participants | ||
| Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose) | Enoxaparin/VKA | 0.8 | Percentage of participants | ||
| Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment | Rivaroxaban (Xarelto, BAY59-7939) | Death (PE) | 0.06 | Percentage of participants | |
| Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment | Enoxaparin/VKA | Death (PE) | 0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00440193/results